GENB says AI drug discovery advances lead GB-0895 program
The company cites AI-driven therapeutics development, including lead program GB-0895 for asthma and COPD, and efforts in oncology to reduce ADC toxicities, supported by partnerships and cash.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.